Teijin completed the acquisition of Ascendis Pharma for $70m.

Teijin, a technology-driven global group, completed the acquisition of Ascendis Pharma, a biopharma company, for $70m. “Ascendis has leveraged its innovative TransCon technology platform to create a suite of highly differentiated product candidates with best-in-class potential that complement our existing pharmaceutical portfolio,” Akimoto Uchikawa, Teijin Limited President and Chief Executive Officer.